Notice Regarding the Recording of Non-Operating Income (Subsidy Income)
The Company (STELLA PHARMA CORPORATION)
Test research concerning angiosarcoma and meningioma, and the “Drug Discovery Support Promotion Project and Practical Application Support Project Before Designation as an Orphan Drug for Rare Diseases”
The Company recorded test research grants from the National Institute of Biomedical Innovation, Health and Nutrition and subsidies from the Japan Agency for Medical Research and Development (AMED) as grant income.
¥53.944 million (non-operating income)
Cumulative second quarter of the fiscal year ending March 2027 (from 1 April 2026 to 30 September 2026)
There is no change to the earnings forecast for the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Event name | Notice Regarding the Recording of Non-Operating Income (Subsidy Income) |
| Date of occurrence | From 1 April 2026 to 30 September 2026 (cumulative second quarter of the fiscal year ending March 2027) |
| Subject Entity | The Company (STELLA PHARMA CORPORATION) |
| Target Locations / Products | Test research concerning angiosarcoma and meningioma, and the “Drug Discovery Support Promotion Project and Practical Application Support Project Before Designation as an Orphan Drug for Rare Diseases” |
| Cause | The Company recorded test research grants from the National Institute of Biomedical Innovation, Health and Nutrition and subsidies from the Japan Agency for Medical Research and Development (AMED) as grant income. |
| Amount of Impact on Business Performance | ¥53.944 million (non-operating income) |
| Accounting period in which recognized | Cumulative second quarter of the fiscal year ending March 2027 (from 1 April 2026 to 30 September 2026) |
| Impact on Earnings Forecast | There is no change to the earnings forecast for the fiscal year ending March 2027. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because test research grants from the National Institute of Biomedical Innovation, Health and Nutrition and subsidies from AMED were recorded.